source
- Daraxonrasib shows promising pancreatic cancer results as Chinese lung therapy exceeds expectationsThe latest ASCO updates highlighted detailed data on daraxonrasib, a drug targeting pancreatic cancer, indicating encouraging efficacy signals for patients. In parallel, a lung cancer treatment de…
- Servier to acquire Edgewise Therapeutics' muscular dystrophy program for up to $2.65 billionFrench pharma group Servier announced it will purchase Edgewise Therapeutics' muscular dystrophy business. The transaction is valued at up to $2.65 billion, comprising a $1.55 billion upfront cash…